Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.69 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | F2R | P25116 | 2/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9063434 | 1.00 | ITGB3 (0.69) | ITGB3ITGA2BF2F10ACE | |
| SCHEMBL24322585 | 0.89 | ITGB3 (0.66) | ITGB3ITGA2BF2F10ACE | |
| SCHEMBL6886518 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BF2F10ACE | |
| SCHEMBL13039757 | 0.77 | ITGB3 (0.71) | ITGB3ITGA2BF2F10ACE | |
| SCHEMBL9056746 | 0.74 | ITGB3 (0.42) | ITGB3ITGA2BF2R | |
| SCHEMBL8915987 | 0.73 | ITGB3 (0.48) | ITGB3ITGA2BF2F10F2R | |
| SCHEMBL7159970 | 0.72 | ITGB3 (0.49) | ITGB3ITGA2BF2F10ACE | |
| SCHEMBL7502425 | 0.66 | ITGB3 (0.79) | ITGB3ITGA2BF2R | |
| SCHEMBL7286054 | 0.65 | ACHE (0.47) | ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL7504932 | 0.65 | ITGB3 (0.78) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560483-B2 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof | XENOPORT, INC. (US) | 2009-07-14 | — | — | US | claimed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6210904-B1 | DIAGNOSING FOR RISK OF THROMOCYTOPENIA BY DETECTING ABSENCE OF ASSOCIATION OF MONOCLONAL ANTIBODY WITH GLYCOPROTEIN IIB/IIA RECEPTOR:GLYCOPROTEIN IIB/IIA RECEPTOR ANTAGONIST COMPLEX | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |
| EP-1034256-A1 | ANTICOAGULANT TEST | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | ITGB3 2084/4885ITGA2B 1654/4885F2 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.